Drug guidance
Nirmatrelvir and ritonavir combination for treating mild-to-moderate COVID-19
Condition
Infections
25 October 2024
Published on 25 Oct 2024
Last Updated on 25 Oct 2024
Guidance Recommendations
The Ministry of Health's Drug Advisory Committee has recommended:
Nirmatrelvir 150 mg tablet and ritonavir 100 mg tablet combination for treating mild-to-moderate Coronavirus Disease 2019 (COVID-19) in patients aged 18 years or older who are immunocompromised.
Funding status
Nirmatrelvir 150 mg tablet and ritonavir 100 mg tablet combination is recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 1 November 2024.
Nirmatrelvir and ritonavir combination should be used in line with the additional clinical criteria listed in the Annex.